Update on Varicose vein n-butyl-2-cyanoacrylate adhesive polymer (VenaSeal™ Closure System), Dermal filler + calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse®), Dalbavancin for IV injection (Xydalba™), Pembrolizumab for IV infusion (Keytruda®)
Update on Human papillomavirus 9-valent vaccine, recombinant (Gardasil®9), Ivermectin 1% cream (Soolantra®), Naftifine HCl 2% gel & cream (Naftin®), Nivolumab IV infusion (Opdivo®), Polymethylmethacrylate collagen dermal filler for acne scars (Bellafill®), Secukinumab SC injection (Consentyx™).
Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).
Update on Omalizumab (Xolair®), Pembrolizumab (Keytruda®), Oritavancin (Orbactiv™), and Calcipotriene 0.005% + betamethasone dipropionate 0.064% topical suspension (Taclonex®)
Update on Tedizolid phosphate tablets and IV injection (Sivextro™), Hyaluronic acidbased dermal filler (Restylane® Silk), Trifarotene, Icatibant SC injection (Firazyr®), C1 esterase inhibitor (Ruconest®), Methotrexate SC injection (Rasuvo™), Tavaborole 5% topical solution (Kerydin™), Nivolumab IV infusion (Opdivo®), Doxycycline hyclate tablets (Acticlate™)
Update on drugs Metronidazole 1.3% vaginal gel (Actavis plc), Ecallantide for SC injection (Kalbitor®), Dalbavancin for IV injection (Dalvance™), Taliglucerase alfa for IV injection (Elelyso™), and Efinaconazole 10% topical solution (Jublia®)
Update on Brimonidine tartrate 0.33% topical gel (Onreltea®Mirvaso®), Apremilast tablets (Otezla®), Miltefosine capsules (Impavido®), Hydrogel wound dressing (Loutrex®), Omalizumab for SC injection (Xolair®), Propranolol hydrochloride oral solution (Hemangeol™), Microbicide-coated condom Vivagel® (SPL7013 gel)
Update on Hyaluronic acid gel dermal filler (Juvéderm Voluma™XC), Methotrexate injection (Otrexup™), Luliconazole 1% cream (Luzu®), Smallpox vaccine (Imvamune®)
Update on Brimonidine tartrate 0.33% topical gel (Mirvaso®), Mechlorethamine gel (Valchlor™), OnabotulinumtoxinA for injection (Botox® Cosmetic), Ustekinumab (Stelara®), Certolizumab pegol (Cimzia®), Infliximab (Inflectra™), Efinaconazole 10% topical solution (Jublia®)
Update on Dabrafenib mesilate capsule (Tafinlar™), Trametinib dimethyl sulfoxide tablet (Mekinist™), and Vismodegib capsule (Erivedge®)
Update on Acyclovir 50 mg buccal tablets (Sitavig®), Acyclovir 5% + hydrocortisone 1% cream (Xerese®), Botulinum toxin type A for injection (Dysport®), Desoximetasone 0.25% topical spray (Topicort®), Carbinoxamine maleate extendedrelease oral suspension (Karbinal™ ER), and C1-esterase inhibitor (Berinert®)
February 2013: Update on drugs, approval dates, and comments. Varicella zoster immune globulin (human) injection (Varizig®), Lidocaine 7% + tetracaine 7% cream (Pliaglis®), Isotretinoin capsule (Epuris™) are covered. Devices such as Laser hair therapy iGrow® Hair Growth Platform and LED device for acne Celluma™ are also covered.
Update on Tofacitinib citrate tablets (Xeljanz®), Lidocaine 7% + tetracaine 7% cream (Pliaglis®), Calcipotriene 0.005% + betamethasone dipropionate 0.064% topical suspension (Taclonex®), Tocilizumab (Actemra®), C1 esterase inhibitor (human) (Cinryze®), and Doxycycline monohydrate 40 mg capsules (Apprilon®)
Update on drugs, approval dates, and comments. Poly-ureaurethane 16% nail solution (Nuvail™), Calcipotriene 0.005% foam (Sorilux™), Hyaluronic acid injectable gel (Restylane-L®) are covered.
Update on Emtricitabine + tenofovir disoproxil fumarate (Truvada®), Collagenase clostridium histolyticum (XIAFLEX®) and devices such as Computer-assisted system for hair follicle harvesting (ARTAS™ System), OTC HIV test (OraQuick® In-Home HIV), and Herpes simplex virus test (IMDx HSV-1/2 for Abbott m2000).
Update on drugs, approval dates, and comments. CIP-Isotretinoin (Absorica™), Tazarotene 0.1% foam (Fabior™), Butoconazole nitrate 2% vaginal cream, Multisource radiofrequency aesthetic device (Glow by EndyMed™), Low-level laser for circumferential upper arm reduction (Zerona®) are covered.
Update on Taliglucerase alfa for injection (Elelyso™ Differin®) as well as devices like Nd:YAG surgical laser (Fotona® XP Laser), Q-switched laser for melasma (Spectra™), Diode hair removal laser (Advantage™), Low-level laser diode device for circumferential reduction (i-Lipo™), Multiwavelength diode laser (Evolve® HPD)
Update on drugs, approval dates, and comments. Belimumab (Benlysta™), Tolnaftate 1% Cream (Tolnaftate-D™), Hydrocortisone 1% Cream (Hydrocortisone-D™), Ketoconazole 2% Foam are covered.
Update on Peginterferon alfa-2b (Sylatron™), Imiquimod 3.75% cream (Zyclara®), experienced recurrence 12 weeks after therapy. (Adapalene 0.1% + benzoyl peroxide 2.5% gel Tactuo™), Collagenase clostridium histolyticum (Xiapex®), and updates on generic drugs.